The CEO's option exercise and sale is a standard cashless exercise pattern, not a bearish signal. The EVP's sale is also routine for a $10B+ biotech. Monitor next earnings for aflatamet (CK-586) pipeline updates, but this insider activity provides no actionable trading signal.
CYTK drugs
CYTK drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 14 $81.93entry
- T+1 · 4mo ago +0.84%α +0.45% · $82.62
- T+5 · 4mo ago −3.44%α −2.15% · $79.11
- T+20 · 3mo ago −6.69%α −9.18% · $76.45
- T+60 · 6w ago −25.40%α −28.78% · $61.12
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Cytokinetics CEO Robert Blum exercised and sold 7,490 shares for ~$614K on July 13, and EVP R&D Fady Malik sold 3,500 shares for ~$303K on July 7. The CEO's sale follows a derivative exercise at $10.60, representing a large realized gain. The total cluster value of ~$917K is ~0.009% of the $10.2B market cap, trivial relative to company size. These are routine liquidity-driven sales, not a bearish signal.
Key Financial Metrics
Key Facts
- CEO Blum exercised 7,490 options at $10.60/share and immediately sold the shares at $82.02, netting ~$614K in proceeds
- EVP R&D Malik sold 3,500 shares at $86.62 for ~$303K on July 7
- Total cluster value of ~$917K represents ~0.009% of CYTK's $10.2B market cap
- Both sales are open-market transactions; no 10b5-1 plan indicated
- Cytokinetics has strong analyst consensus (89% bullish) with 25 buy-equivalent ratings
Financial Impact
Total insider sales of ~$917K, less than 0.01% of market cap, immaterial
Risk Factors
- Insider sales could increase if additional option exercises occur near expiration
- No 10b5-1 plan disclosed, future sales may be unpredictable
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-CYTK-1784057701171 |
Track record
46 reports on CYTK
7 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +8.59% at T+20 after the Sep 15, 2026 report. 10 of 11 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $53.76 Now $53.17 −1.10% settles Dec 15
- Nov 12, 20264d ago Insider Cluster Neutral 3/10 Entry $56.13 Now $53.17 −5.27% settles Dec 14
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $56.18 Now $53.17 −5.36% settles Dec 9
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $56.18 Now $53.17 −5.36% settles Dec 9
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $55.14 Now $53.17 −3.57% settles Dec 8
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $55.14 Now $53.17 −3.57% settles Dec 8
- Nov 4, 202612d ago 8-K Bullish 6/10 No price data
- Nov 4, 202612d ago Press Release Neutral 5/10 Entry $55.55 Now $53.17 −4.28% settles Dec 4
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $63.60 Now $53.17 −16.40% settles Dec 3
- Nov 2, 202614d ago Press Release Neutral 3/10 Entry $62.03 Now $53.17 −14.28% settles Dec 1
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers